{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000000", "text": "# ESMO_CPG_NonEpithelialOvarian_2018", "section": "ESMO_CPG_NonEpithelialOvarian_2018", "page_from": null, "page_to": null, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "6f2c1ab98846b9d470f20e8aa05ea1ebdbd9a67dbac2cce42985165b2c2a1a56"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000001", "text": "CLINICAL PRACTICE GUIDELINES\nNon-epithelial ovarian cancer: ESMO Clinical Practice\nGuidelines for diagnosis, treatment and follow-up†\nI. Ray-Coquard1, P. Morice2, D. Lorusso3, J. Prat4, A. Oaknin5, P. Pautier2 & N. Colombo6, on behalf of the\nESMO Guidelines Committee*\n1Centre Leon Be´rard, University Claude Bernard Lyon & GINECO group, Lyon; 2Gustave Roussy & GINECO group, Villejuif, France; 3Fondazione IRCCS Istituto\nNazionale dei Tumori, Milan, Italy; 4Hospital de Sant Pau, Autonomous University of Barcelona; 5Vall d’Hebron University Hospital, Vall d’Hebron Institute of\nOncology (VHIO), Barcelona, Spain; 6University of Milan-Bicocca and European Institute of Oncology, Milan, Italy\n*Correspondence to: ESMO Guidelines Committee, ESMO Head Ofﬁce, Via L. Taddei 4, CH-6962 Viganello-Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org\n†Approved by the ESMO Guidelines Committee: August 2008, last update December 2017. This publication supersedes the previously published version—Ann Oncol 2012;\n23(Suppl 7): vii20–vii26.\nIncidence and epidemiology\nNon-epithelial ovarian tumours account for approximately 10%\nof all ovarian cancers. Malignant germ cell tumours (GCTs)", "section": "CLINICAL PRACTICE GUIDELINES", "page_from": 1, "page_to": 1, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "3734c8cc987a500b920e7b65cd026ae79c25216709a24921842b4ecb6d16f214"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000002", "text": "23(Suppl 7): vii20–vii26.\nIncidence and epidemiology\nNon-epithelial ovarian tumours account for approximately 10%\nof all ovarian cancers. Malignant germ cell tumours (GCTs)\noccur mainly in young women whereas the most common type of\nsex cord-stromal tumours (SCSTs), i.e. granulosa cell tumour,\noccurs more often in middle age and in postmenopausal women\n[1]. Malignant GCTs represent 5% of all ovarian cancers and\n80% of the preadolescent malignant ovarian tumours. SCSTs are\nrare neoplasms that account for approximately 3%–5% of\novarian malignancies and the majority of ovarian tumours with\nendocrine manifestations. The yearly-adjusted incidence rate is\n3.7/1 000 000 and 2.1/1 000 000 women for GCTs and SCSTs,\nrespectively [1]. Small cell carcinoma of the ovary (SCCO) usu-\nally affects young women and children [2] with a very low inci-\ndence (less than 1% of ovarian cancers) [1]. Unlike GCTs, SCSTs\nand steroid cell tumours are unilateral and occur over a wide\nrange of age; for instance, granulosa cell tumours and thecomas\nare found mainly in peri- and postmenopausal women, whereas\njuvenile granulosa cell tumours, Sertoli cell tumours and Sertoli–", "section": "CLINICAL PRACTICE GUIDELINES", "page_from": 1, "page_to": 1, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "f4fa8cab3f3fe93e68b4924030ec68def8f25c98c3fbfeba2d0a8ac12985ea2b"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000003", "text": "range of age; for instance, granulosa cell tumours and thecomas\nare found mainly in peri- and postmenopausal women, whereas\njuvenile granulosa cell tumours, Sertoli cell tumours and Sertoli–\nLeydig cell tumours (SLCTs) usually develop in adolescents and\nyoung females in whom maintenance of fertility is important [3].\nDiagnosis and pathology/molecular biology\nThe initial symptoms and signs of non-epithelial ovarian cancers\nare usually a subacute pelvic pain, feeling of pelvic pressure because\nof a pelvic mass and menstrual irregularities. Diagnostic work-up\nshould include pelvic ultrasound, abdomino-pelvic computed\ntomography (CT) scan, chest X-ray and positron emission tomog-\nraphy (PET) scan in selected cases (GCTs) [III, B]. In young\npatients, serum human chorionic gonadotropin (hCG), alpha-\nfoetoprotein (a-FP) and lactate dehydrogenase (LDH) levels, full\nblood count and liver and renal function tests should be carried\nout. Inhibin B is secreted by granulosa cell tumours and could be a\nuseful marker for the disease. Serum anti-Mu¨llerian hormone\n(AMH) may be a marker of ovarian reserve and granulosa cell\ntumours in postmenopausal or post-oophorectomy women [4].", "section": "CLINICAL PRACTICE GUIDELINES", "page_from": 1, "page_to": 1, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "cc1c109d8ed411122d10e014a921b7ec3a53f876b476dfb72e96d2fdb68fd1e6"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000004", "text": "useful marker for the disease. Serum anti-Mu¨llerian hormone\n(AMH) may be a marker of ovarian reserve and granulosa cell\ntumours in postmenopausal or post-oophorectomy women [4].\nWhile these markers are nonspeciﬁc, they can provide prognostic\ninformation, so quantitative hCG, a-FP, LDH and cancer antigen\n125 (CA 125) should be measured preoperatively [5]. If gonado-\nblastoma is suspected, a preoperative karyotype should be\nobtained on all premenarche girls because of the propensity of\nthese tumours to arise in dysgenetic gonads.\nMost non-epithelial ovarian tumours arise from cells speciﬁc\nto the ovary (germ cells, granulosa cells, theca cells, stromal ﬁbro-\nblasts and steroid cells); other less common gonadal tumours\narise from non-speciﬁc ovarian cells (mesenchymal cells). The\nWorld Health Organization (WHO) classiﬁcation of GCTs is pre-\nsented in Table 1 [6, 7]. GCTs recapitulate steps of development,\nfrom undifferentiated germ cells to adult tissues. Primitive GCTs\ncomposed of undifferentiated germ cells and GCTs with extraem-\nbryonic differentiation are all malignant. Teratomas are the most\ncommon GCTs; most are composed of mature tissues and are", "section": "CLINICAL PRACTICE GUIDELINES", "page_from": 1, "page_to": 1, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "7b83c06953c1de5d53864d652a746884b3c0e94956fae0df745a38e127dd8bb9"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000005", "text": "composed of undifferentiated germ cells and GCTs with extraem-\nbryonic differentiation are all malignant. Teratomas are the most\ncommon GCTs; most are composed of mature tissues and are\nbenign (dermoid cysts). In immature teratomas, embryonic tis-\nsues indicate the malignant potential and grading is prognosti-\ncally relevant [7]. Grade 1 tumours show rare foci of immature\nneuroepithelial tissue that occupy < 1 low power ﬁeld (40\u0002) in\nany slide (low grade); grade 2 tumours show similar elements,\noccupying 1–3 low power ﬁelds (40\u0002) in any slide (high grade);\ngrade 3 tumours exhibit large amounts of immature neuroepithe-\nlial tissue occupying > 3 low power ﬁelds (40\u0002) in any slide (high\nV\nC The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.\nAll rights reserved. For Permissions, please email: journals.permissions@oup.com.\nAnnals of Oncology 29 (Supplement 4): iv1–iv18, 2018\ndoi:10.1093/annonc/mdy001\nPublished online 25 April 2018; updated 04 October 2018", "section": "CLINICAL PRACTICE GUIDELINES", "page_from": 1, "page_to": 1, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "3a06db89eb069627516690e5fe55ae90834f1ec4a6ea40e83fd9e8cc08def81d"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000006", "text": "grade). A two-tiered (low and high grades) system is now more\ncommonly used [8]. Other rare malignant GCTs constitute a het-\nerogeneous group including somatic cancers arising in dermoids\nand\nmonodermal\nteratomas\n[7].\nIn\nthe\nelderly,\nnon-\ndysgerminoma GCTs arise from epithelial ovarian cancer, usually\nendometrioid and clear cell carcinomas. Primitive GCTs and\nimmature teratomas are chemosensitive and susceptible to\nfertility-sparing surgery. Because of their chemosensitivity and\nthe increasing adoption of fertility-sparing surgery, correct\npathological diagnosis is essential and these cases should be\nexamined by gynaecological pathologists [V, B]. Diagnosis can be\nmade on conventional histological material; given the multiplic-\nity of morphological features, immunohistochemical markers\n(Table 2) and chromosome 12p ﬂuorescent in situ hybridisation\n(FISH) can be used to conﬁrm the diagnosis in difﬁcult cases.\nSALL4 and OCT4 are widely used; more recently, it has been rec-\nognised that SOX2 is expressed in embryonal carcinoma and\nprimitive neuroectodermal tumours of teratomatous origin.\nSCSTs and steroid cell tumours constitute a heterogeneous", "section": "CLINICAL PRACTICE GUIDELINES", "page_from": 2, "page_to": 2, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "8879c49d0094627c52b909ac98cd90b345005990f02f9a1a5da7579528c020a8"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000007", "text": "ognised that SOX2 is expressed in embryonal carcinoma and\nprimitive neuroectodermal tumours of teratomatous origin.\nSCSTs and steroid cell tumours constitute a heterogeneous\ngroup of tumours (Table 3) and vary in their capacity to produce\nclinically signiﬁcant amounts of steroid hormones. Granulosa\ncell tumours are typically oestrogenic and may be associated with\nvarious clinical syndromes, depending upon the age of the\npatient. SLCTs typically produce androgens, and clinical virilisa-\ntion is observed in 70%–85% of patients. Those with sex cord ele-\nments may be malignant, with granulosa cell tumours being the\nmost frequent histological type. Neoplasms of pure ovarian\nstroma are mostly benign, with > 50% of them being ﬁbromas.\nIn morphologically ambiguous cases, an immunopanel of inhibin\nalpha, calretinin and FOXL2, together with FOXL2 (402C-G)\nmutational analysis, is useful to conﬁrm the diagnosis of adult\ngranulosa cell tumours (AGCTs) [V, B] [9]. Chang et al. demon-\nstrated that another molecule involved in the tumourigenesis of\nAGCTs is activin A [10]. A subset of SCSTs is typically negative\nfor FOXL2 on immunostaining (retiform or poorly differentiated", "section": "CLINICAL PRACTICE GUIDELINES", "page_from": 2, "page_to": 2, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "b12ae45e40b83bad585d7a2c1d708c2d18e84e9623daa4feadd7e0e40f0eb60d"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000008", "text": "strated that another molecule involved in the tumourigenesis of\nAGCTs is activin A [10]. A subset of SCSTs is typically negative\nfor FOXL2 on immunostaining (retiform or poorly differentiated\nSLCT), but these tumours usually express inhibin alpha and/or\ncalretinin. Another recent ﬁnding has been the occurrence of\nDICER1 mutations in SCST [V, C].\nSmall cell carcinomas of the ovary hypercalcaemic type\n(SCCOHTs) are the most common form of ovarian undifferenti-\nated carcinomas in women < 40years old and the most common\novarian tumour associated with hypercalcaemia (70%). This\ntumour is typically unilateral and should be distinguished from\nprimitive GCTs and granulosa cell tumours (mainly juvenile).\nAlthough its histogenesis is unknown, recent reports suggest that it\nmay represent an ovarian malignant rhabdoid tumour [11].\nRecent studies have identiﬁed mutations in the SWItch/Sucrose\nNon-Fermentable\n(SWI/SNF)\nchromatin-remodelling\ngene,\nSMARCA4 encoding BRG1. These mutations represent a frequent\nevent occurring in 76%–100% of SCCOHTs [12–14]. Germline\nmutations in SMARCA4 or SMARCB1 were already known to pre-\ndispose to the development of paediatric tumours, namely atypical", "section": "CLINICAL PRACTICE GUIDELINES", "page_from": 2, "page_to": 2, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "97ce6bd7dffeb82d263f0be7e22ef3fee11f862955456d20265d159b60306725"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000009", "text": "event occurring in 76%–100% of SCCOHTs [12–14]. Germline\nmutations in SMARCA4 or SMARCB1 were already known to pre-\ndispose to the development of paediatric tumours, namely atypical\nteratoid/rhabdoid tumours [15, 16]. SMARCA4 immunohisto-\nchemistry is highly sensitive and speciﬁc for a diagnosis of\nSCCOHT [loss of SMARCA4 (BRG1) protein expression] and is\nnow useful in the differential diagnosis of poorly differentiated\novarian tumours [17]. SCCOHTs usually react diffusely for WT1,\nmaking the interpretation difﬁcult. Differential diagnosis includes\nTable 1. WHO 2014 classiﬁcation of GCTs [6]\nDysgerminoma\nYolk sac tumour\nEmbryonal carcinoma\nNon-gestational choriocarcinoma\nMature teratoma\nImmature teratoma\nMixed germ cell tumour\nGCT, germ cell tumour; WHO, World Health Organization.\nTable 2. Immunohistochemistry of primitive GCTs\nSall4\nOCT3/4\nSOX2\nDys\nþ\nþ\n–\nYST\nþ\n–\n–\nEC\nþ\nþ\nþ\nDys, dysgerminoma; EC, embryonal carcinoma; GCT, germ cell tumour;\nYST, yolk sac tumour.\nTable 3. WHO 2014 classiﬁcation of SCSTs and steroid cell tumours [7]\nPure stromal tumours\nFibroma\nCellular ﬁbroma\nThecoma\nLuteinized thecoma associated with sclerosing peritonisis\nFibrosarcoma\nSclerosing stromal tumour", "section": "CLINICAL PRACTICE GUIDELINES", "page_from": 2, "page_to": 2, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "b64c0f9dbac6c9ab30c0faa086aef7394d39d6983af9851b977f05cecd2e859a"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000010", "text": "Pure stromal tumours\nFibroma\nCellular ﬁbroma\nThecoma\nLuteinized thecoma associated with sclerosing peritonisis\nFibrosarcoma\nSclerosing stromal tumour\nSignet-ring stromal tumour\nMicrocystic stromal tumour\nLeydig cell tumour\nSteroid cell tumour\nSteroid cell tumour, malignant\nPure sex cord tumours\nAdult granulosa cell tumour\nJuvenile granulosa cell tumour\nSertoli cell tumours\nSex cord tumour with annular tubules\nMixed sex cord-stromal tumours\nSertoli–Leydig cell tumours\nWell differentiated\nModerately differentiated\nWith heterologous elements\nPoorly differentiated\nWith heterologous elements\nRetiform\nWith heterologous elements\nSex cord-stromal tumours, NOS\nNOS, not otherwise speciﬁed; SCST, sex cord-stromal tumour; WHO,\nWorld Health Organization.\nClinical Practice Guidelines\nAnnals of Oncology\niv2 | Ray-Coquard et al.\nVolume 29 | Supplement 4 | October 2018", "section": "CLINICAL PRACTICE GUIDELINES", "page_from": 2, "page_to": 2, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "2964e7ce3b5d61aa60b8ee0cabe683b63a01a314011f1300a3a0815218932cc7"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000011", "text": "juvenile or adult granulosa tumours, metastatic melanoma, dys-\ngerminoma, Ewing tumour and undifferentiated carcinoma.\nStaging and risk assessment\nPrognostic factors\nThe staging system for non-epithelial ovarian cancers is generally\nadopted from the one for epithelial ovarian cancer originally\ndeﬁned by the International Federation of Gynecology and\nObstetrics (FIGO) (Table 4) [18]. Outcomes appear to be supe-\nrior when patients are treated in a large cancer centre, likely due\nto the rare nature and infrequent presentation of these cancers\n[19].\nOutcomes may depend on the age at diagnosis. Premenarche\ngirls and women > 45 years who develop GCTs may have differ-\nent tumour biology and a worse prognosis than postadolescent\nfemales in the reproductive years. Patients with testicular cancer\nare stratiﬁed as having good, intermediate or high risk for\nrecurrence based on clinical, pathological and serological\nmarkers. Compared with testicular cancer, clinical prognostica-\ntors are less well deﬁned for ovarian GCTs. Adverse factors\ninclude age > 45 years, stage > I, incomplete surgical resection\nand yolk sac tumour (YST) histology [20, 21].", "section": "Staging and risk assessment", "page_from": 3, "page_to": 3, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "8867ba09accc85bfac8bb2c0508277bfab2306ec006491a635cff70acd38b410"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000012", "text": "tors are less well deﬁned for ovarian GCTs. Adverse factors\ninclude age > 45 years, stage > I, incomplete surgical resection\nand yolk sac tumour (YST) histology [20, 21].\nStage is also an important prognostic factor for SCSTs,\nalthough advanced-stage diseases can also have a good prognosis\nbecause of their sensitivity to chemotherapy (ChT). The FIGO\nstage [18] and the intraperitoneal tumour rupture are the most\noften reported prognostic factors. Patient age (> 50 years) and\nthe size of the tumour (> 5 cm) have a less certain prognostic\nvalue [5]. The majority of these tumours can be cured, but\naround 20% relapse or give rise to metastases that can be fatal\n[III, A].\nPrognosis of SCCOHT is poor with only 30%–40% long-term\nsurvivors with standard treatment [2]. Potential favourable prog-\nnostic factors, in addition to disease stage (stage IA versus others)\nare: age > 30 years; normal pre-operative calcium level; a tumour\nsize < 10 cm; the absence of large cells; and complete surgical\nresection including bilateral oophorectomy [22, 23].\nTable 4. 2014 FIGO ovarian cancer staging system and corresponding TNM\nTNM staging\nFIGO staging\nDescription\nT1a-N0-M0\nStage IA", "section": "Staging and risk assessment", "page_from": 3, "page_to": 3, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "342b5b99b055e5b5b295e497ec398daf451d670b943889470d9446265ccf7ed0"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000013", "text": "resection including bilateral oophorectomy [22, 23].\nTable 4. 2014 FIGO ovarian cancer staging system and corresponding TNM\nTNM staging\nFIGO staging\nDescription\nT1a-N0-M0\nStage IA\nTumour limited to one ovary (capsule intact), no tumour on ovarian surface; no malignant\ncells in ascites or peritoneal washings; no regional lymph node metastasis; no distant\nmetastasis\nT1b-N0-M0\nStage IB\nTumour limited to both ovaries (capsules intact), no tumour on ovarian surface; no malignant\ncells in ascites or peritoneal washings; no regional lymph node metastasis; no distant\nmetastasis\nT1c-N0-M0\nStage IC1\nTumour limited to one or both ovaries with capsule ruptured (surgical spill); no regional\nlymph node metastasis; no distant metastasis\nT1c-N0-M0\nStage IC2\nTumour limited to one or both ovaries with capsule ruptured before surgery or tumour on\novarian surface; no regional lymph node metastasis; no distant metastasis\nT1c-N0-M0\nStage IC3\nTumour limited to one or both ovaries with malignant cells in ascites or peritoneal washings;\nno regional lymph node metastasis; no distant metastasis\nT2a-N0-M0\nStage IIA\nExtension and/or implants on the uterus and/or tube(s); no malignant cells in ascites or peri-", "section": "Staging and risk assessment", "page_from": 3, "page_to": 3, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "86b695ae4086bebfc84eacf5ea9938b5d07c8c1c349e00f922dc4f52d86af0db"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000014", "text": "no regional lymph node metastasis; no distant metastasis\nT2a-N0-M0\nStage IIA\nExtension and/or implants on the uterus and/or tube(s); no malignant cells in ascites or peri-\ntoneal washings; no regional lymph node metastasis; no distant metastasis\nT2b-N0-M0\nStage IIB\nExtension to and/or implants in other pelvic tissues; no malignant cells in ascites or perito-\nneal washings; no regional lymph node metastasis; no distant metastasis\nT1/T2-N1-M0\nStage IIIA1\nStage IIIA1 (i)\nStage IIIA1 (ii)\nTumour limited to the ovaries (one or both) (T1) or tumour involves one or both ovaries\nwith pelvic extension (T2); regional lymph node metastasis; no distant metastasis\nMetastasis up to 10 mm in greatest dimension\nMetastasis more than 10 mm in greatest dimension\nT3a-N0/N1-M0\nStage IIIA2\nMicroscopic peritoneal metastasis beyond the pelvis (no macroscopic tumour); no regional\nlymph node metastasis (N0) or regional lymph node metastasis (N1); no distant metastasis\nT3b-N0/N1-M0\nStage IIIB\nMacroscopic peritoneal metastasis beyond the pelvis up to 2 cm in greatest dimension; no\nregional lymph node metastasis (N0) or regional lymph node metastasis (N1); no distant\nmetastasis\nT3c-N0/N1-M0\nStage IIIC", "section": "Staging and risk assessment", "page_from": 3, "page_to": 3, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "9f6ab5b3b611a4cd25f8702cebf140e75f9fa2a2286a3c9a79f91022c7db8ee4"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000015", "text": "regional lymph node metastasis (N0) or regional lymph node metastasis (N1); no distant\nmetastasis\nT3c-N0/N1-M0\nStage IIIC\nMacroscopic peritoneal metastasis beyond the pelvis > 2 cm in greatest dimension and/or\nregional lymph node metastasis; no regional lymph node metastasis (N0) or regional\nlymph node metastasis (N1); no distant metastasis\nany T-any N-M1\nStage IVA\nPleural effusion with positive cytology\nany T-any N-M1\nStage IVB\nParenchymal metastases and metastases to extra-abdominal organs (including inguinal\nlymph nodes and lymph nodes outside of the abdominal cavity)\nFIGO, International Federation of Gynecology and Obstetrics; TNM, tumour, node, metastasis.\nModiﬁed from [22] and [57].\nAnnals of Oncology\nClinical Practice Guidelines\nVolume 29 | Supplement 4 | October 2018\ndoi:10.1093/annonc/mdy001 | iv3", "section": "Staging and risk assessment", "page_from": 3, "page_to": 3, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "2be9c735e5ae733b187d37194a3866f49ff3b76196e97d867fab89a7dbee40f3"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000016", "text": "Staging\nA surgical approach can be carried out through open route or, in\nselected cases, by minimally invasive approaches—laparoscopy\nand robotics—to avoid tumour rupture during surgery. A careful\nexamination of the abdominal cavity is required. The staging pro-\ncedure includes infracolic omentectomy, biopsy of the diaphrag-\nmatic peritoneum, paracolic gutters, pelvic peritoneum and\nperitoneal washings in macroscopic stage I disease.\nGerm cell tumours. There is no consensus about the role of sys-\ntematic lymphadenectomy, but the omission of staging perito-\nneal procedures seems to increase the recurrence rate [24],\nthough without impact on overall survival [25]. GCTs, particu-\nlarly dysgerminoma, have a high risk of nodal spread. On the\nother hand, given the very high chemosensitivity of such\ntumours, potential nodal metastasis should be cured by adjuvant\nChT in these patients [III, A].\nThus, nodal debulking surgery is only required in rare cases of\nresidual disease after ChT. In early-stage disease that does not\nrequire adjuvant ChT because of favourable prognostic factors,\nnodal dissection should be carried out only where there is evi-", "section": "Staging", "page_from": 4, "page_to": 4, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "83eb479e5109264276f03474704d227e1beed71046e8be9f83f1d6011502edf3"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000017", "text": "residual disease after ChT. In early-stage disease that does not\nrequire adjuvant ChT because of favourable prognostic factors,\nnodal dissection should be carried out only where there is evi-\ndence of nodal abnormalities during surgical exploration and/or\ninitial CT scan (lymphadenopathy) [III, A]. Patients not under-\ngoing initial nodal staging surgery can be safely cured with ChT at\nthe time of the potential nodal recurrence [26].\nUnilateral salpingo-oophorectomy with preservation of the\ncontralateral ovary and the uterus is now considered as the stand-\nard surgical treatment for young patients with GCTs [III, A].\nThis conservative management should be considered even in\nthe case of advanced disease because of the sensitivity of the\ntumour to ChT [IV, B] [27]. Systematic ovarian biopsy is not nec-\nessary when the contralateral ovary is macroscopically normal [III,\nA]. In case of macroscopic bilateral ovarian diseases (particularly\ndysgerminoma or immature teratoma), preservation of at least a\nhealthy part of one ovary (unilateral salpingo-oophorectomy and\ncontralateral cystectomy) and the uterus should be encouraged\n[IV, B] [28]. In postmenopausal women and in patients with", "section": "Staging", "page_from": 4, "page_to": 4, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "62f970eaf000a483c255a785029f95e77278b280c76537ad1e8c874f4d1281f8"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000018", "text": "healthy part of one ovary (unilateral salpingo-oophorectomy and\ncontralateral cystectomy) and the uterus should be encouraged\n[IV, B] [28]. In postmenopausal women and in patients with\nadvanced-stage disease or with bilateral ovarian involvement,\nabdominal hysterectomy and bilateral salpingo-oophorectomy\ncould be carried out with careful surgical staging [III, A].\nSex cord-stromal tumours. The place of conservative treatment in\nchild-bearing age patients affected by SCSTs is somewhat differ-\nent. Preservation of the uterus and contralateral ovary seems to\nbe safe in macroscopic stage IA disease but should not be carried\nout in stages > I. Conservative surgery is also an acceptable\napproach in young patients with stage I SCSTs [IV, B]. In the case\nof juvenile granulosa cell tumours, the safety of this management\napproach in stage IC disease remains controversial, particularly\nin stage IC2 or IC3 disease [V, C]. In case of conservative treat-\nment, an endometrial curettage (or hysterectomy in case of radi-\ncal management) must be carried out to rule out concomitant\nuterine cancers in patients with granulosa cell tumour [IV, B].", "section": "Staging", "page_from": 4, "page_to": 4, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "52393455521355c5507ae15b728d3af68c0bd48243e6225c1eea576b93d640bb"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000019", "text": "ment, an endometrial curettage (or hysterectomy in case of radi-\ncal management) must be carried out to rule out concomitant\nuterine cancers in patients with granulosa cell tumour [IV, B].\nFor SCSTs, retroperitoneal evaluation is not mandatory because\nof the very low incidence of retroperitoneal metastases in early-\nstage disease [III, A]. Recent publications on incidence of lymph\nnode metastases in SCST support the position that lymphadenec-\ntomy is not needed in these patients [29]. SLCTs frequently have\nlow-grade malignancy, although occasionally a retiform or\npoorly differentiated (sarcomatoid) form may be malignant. In\npostmenopausal women and in patients with advanced-stage dis-\nease or with bilateral ovarian involvement, abdominal hysterec-\ntomy and bilateral salpingo-oophorectomy should be carried out\nwith careful surgical staging for SCST [III, A].\nSmall cell carcinomas of the ovary hypercalcaemic type. The prog-\nnosis of SCCOHT is very poor and the risk of extra-ovarian spread\nhigh. All suspected cases should beneﬁt from a review by an expert\npathologist and be discussed in a specialised tumour board [V, A].\nEfforts should be made to treat patients in a more homogeneous", "section": "Staging", "page_from": 4, "page_to": 4, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "fd46ce3bb96bc17bce639e6192c6fac92c3742b2da33de2134bfcd79e07b7a3c"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000020", "text": "high. All suspected cases should beneﬁt from a review by an expert\npathologist and be discussed in a specialised tumour board [V, A].\nEfforts should be made to treat patients in a more homogeneous\nway through national and international networks [V, A].\nConventional surgical treatment includes radical surgery (bilateral\nsalpingo-oophorectomy and hysterectomy) combined with perito-\nneal and nodal staging surgery, even for macroscopically stage I dis-\nease [IV, A] [2]. The largest series to date reported a decline in\nsurvival in patients treated conservatively [2]. As a result of the adju-\nvant treatment after surgery combining high-dose ChT (HDCT)\nand radiotherapy (RT), the potential preservation of gonadal func-\ntion is considered to be only conceptual even if one ovary and the\nuterus are preserved [2]. Until now, no pregnancy has been reported\nafter this type of de-escalating surgical management [2].\nManagement of early stages\nGerm cell tumours (Figures 1–3)\nMost GCTs (60%–70%) are diagnosed at an early stage. Stage I\npatients have an excellent prognosis with long-term disease-free status\nof about 90%. Given the young age of patients, all efforts should be", "section": "Staging", "page_from": 4, "page_to": 4, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "0eac5cb422fd8f40ffd36f15a6ac4dda00d5a4058b5aa8d3329a982955136b55"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000021", "text": "patients have an excellent prognosis with long-term disease-free status\nof about 90%. Given the young age of patients, all efforts should be\nmade to preserve fertility. Fertility-sparing surgery appears to be safe\nwith excellent survival after long-term follow-up, yielding outcomes\nequivalent to patients undergoing hysterectomy with bilateral\nsalpingo-oophorectomy [III, A]. Stage IA pure dysgerminoma should\nbe treated with surgery only [III, A] [24]. The recurrence rate in this\ngroupof patients is relatively low (15%–25%) and they can be success-\nfully treated at the time of relapse with a high likelihood of cure.\nPatients with stage IA grade 1 immature teratoma do not require fur-\nther adjuvant ChT after adequate surgical staging [III, A]. The need\nfor adjuvant ChT in stage IA G2–G3 and IB–IC is still controversial\n[5]. Some published data (risk of relapse ranging from 2%–20% for\ngrade 2 to 20%–40% for grade 3 immature teratoma) indicate that all\ngrades of immature teratoma and all stage I dysgerminomas can be\nmanaged with close surveillance after fertility-sparing surgery [III, B],\nreserving ChT for those cases in which post-surgery recurrence is", "section": "Staging", "page_from": 4, "page_to": 4, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "42decb27fbaf25dc4eda6b78f11cc5cd9565a8ca4e4d2bb6ccf3e5c4242d30ce"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000022", "text": "managed with close surveillance after fertility-sparing surgery [III, B],\nreserving ChT for those cases in which post-surgery recurrence is\ndocumented [24, 30]. However, this policy is not universally accepted;\nthe beneﬁt of not having ChT (i.e. the avoided risk weighed against\nthe risk of relapse and delayed treatment) needs to be discussed with\nthe patient. All patients with stage I YSTs are treated with adjuvant\nChTaftersurgery[31].Recentdataonpaediatric patientssuggestclose\nsurveillance for stage I YSTs with complete surgical staging and nega-\ntive postoperative a-FP, reserving ChT for patients who experience\nrecurrence [30], but this policy is not widely accepted [III, C].\nData from the literature show that the most used combination\nis the 5-day bleomycin/etoposide/cisplatin (BEP) regimen [III,\nA] [31].\nClinical Practice Guidelines\nAnnals of Oncology\niv4 | Ray-Coquard et al.\nVolume 29 | Supplement 4 | October 2018", "section": "Staging", "page_from": 4, "page_to": 4, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "4f82a7e09ee2d35d5586103b9b682f50b0e2676ae0696e25266fc44fa403bb8f"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000023", "text": "When ChT is not offered, a close and active surveillance pro-\ngramme should be proposed [III, C]. Vazquez and Rustin postulate\na surveillance schedule involving regular clinical review with clinical\nexamination,\nradiological\nimaging\nincluding\nabdomen-pelvic\nsonography at regular intervals and the monitoring of tumour\nmarkers to detect relapse over a period of 10years, with a gradual\nDysgerminoma\nStage IA\nStage IB-IC\nStage IIA-IV\nFertility-sparing surgery\nSurgical staging\n[III, A]\nFertility-sparing surgery\n Surgical staging\n [III, A]\nDebulking/Staging [III, A]\nor\nFertility-sparing surgery\nwhen indicated [IV, B]\nProperly-staged\npatients\nBEP x 3–4 cycles\n[III, A]\nEP x 3-4 cycles\n[III, A]\nNo\nYes\n≤ 40 years\n> 40 years\nor with PD\nActive surveillance*\nStandard follow-up\nFigure 1. Management of GCTs of the ovary—dysgerminoma.\n*See Table 5.\nBEP, bleomycin/etoposide/cisplatin; EP, etoposide/cisplatin; GCT, germ cell tumour; PD, pulmonary disease.\nAnnals of Oncology\nClinical Practice Guidelines\nVolume 29 | Supplement 4 | October 2018\ndoi:10.1093/annonc/mdy001 | iv5", "section": "Staging", "page_from": 5, "page_to": 5, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "4df19e3715da338d7b8ceafc23a31bc68af79e3518afe6e74da2a13b1efe7c15"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000024", "text": "Immature teratoma\nStage IA G1\nStage IA G2-G3\nStage IB-IC\nStage IIA-IV\nFertility-sparing surgery when indicated\nSurgical staging\n[III, A]\nActive surveillance*\nStandard follow-up\nDebulking/Staging\n[III, A]\nFertility-sparing\nsurgery in some cases\n[IV, B]\nBEP x 3–4 cycles [III, A]\nProperly-staged patients\nwith negative\npostoperative\ntumour markers\nCytoreductive surgery\nif residual disease\n[III, A]\nSelected cases\nFigure 2. Management of GCTs of the ovary—immature teratoma.\n*See Table 5.\nOptional\nBEP, bleomycin/etoposide/cisplatin; GCT, germ cell tumour.\nClinical Practice Guidelines\nAnnals of Oncology\niv6 | Ray-Coquard et al.\nVolume 29 | Supplement 4 | October 2018", "section": "Immature teratoma", "page_from": 6, "page_to": 6, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "fb1877c5b8e99f2c3a6b8e8556b340598d039a876df0d554d85496fd5a1913c6"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000025", "text": "Active surveillance*\n[GoR C]\nYolk sac tumour\nStage IA-IB\nStage IC-IV\nFertility-sparing surgery\nStaging\n[III, A]\nDebulking/Staging\n[III, A]\nor\nFertility-sparing surgery\nStaging\n[IV, B]\nStandard follow-up\nBEP x 3–4 cycles [III, A]\nProperly-staged patients\nwith negative\npostoperative\ntumours markers\nFigure 3. Management of GCTs of the ovary—yolk sac tumour.\n*See Table 5.\nOptional\nBEP, bleomycin/etoposide/cisplatin; GCT, germ cell tumour; GoR, grade of recommendation.\nAnnals of Oncology\nClinical Practice Guidelines\nVolume 29 | Supplement 4 | October 2018\ndoi:10.1093/annonc/mdy001 | iv7", "section": "Yolk sac tumour", "page_from": 7, "page_to": 7, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "cef403b52e5f77940a5acdcd667393bccbfbfa4bcd355dffd49a37b3101710e9"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000026", "text": "increase of the interval between clinical appointments [III, C] [32].\nThis is summarised in Table 5 [32]. Patient adherence to the\ndemanding visit schedule is of paramount importance. It is\nextremely important to advise patients against pregnancy during the\nﬁrst 2years after initial diagnosis, as most relapses occur during this\ntime [1]. Whenever possible, patients undergoing active surveillance\nprotocols should be included in trials or prospective registries.\nSex cord-stromal tumours (Figures 4 and 5)\nMost SCSTs (60%–95%) are diagnosed at an early stage. Stage IA\ngranulosa cell tumours have an excellent prognosis after surgery\nalone and do not require adjuvant therapy [III, A].\nThe selection of early-stage SCST patients for any postopera-\ntive treatment is controversial. To date, the relative beneﬁt of\nadjuvant ChT has yet to be demonstrated. Some authors would\nsuggest adjuvant therapy for juvenile granulosa tumour stage IC\npatients [IV, B]; in this case, platinum-based ChT is the treatment\nof choice [III, A]. Also, more relapses were reported for patients\nwith AGCT stage IC2 compared with stage IC1 [33]; in this case,\nadjuvant ChT can be discussed [IV, C].", "section": "Yolk sac tumour", "page_from": 8, "page_to": 8, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "c73cf1c800ecdb5d70a9cf1440968cc69787b1c897473cb1cbfd2b9a9df3519b"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000027", "text": "of choice [III, A]. Also, more relapses were reported for patients\nwith AGCT stage IC2 compared with stage IC1 [33]; in this case,\nadjuvant ChT can be discussed [IV, C].\nThe most commonly used regimen is the BEP combination [III,\nA] [5]. Alternative ChT options include: paclitaxel and carboplatin\n[III, B] [34]; etoposide/cisplatin (EP); cyclophosphamide/doxorubi-\ncin/cisplatin (CAP); or a platinum agent alone [III, A]. Due to the rel-\native toxicity of BEP versus carboplatin/paclitaxel, particularly in\nolder age groups, and the limited evidence to support its use (some\nnon-randomised series suggest carboplatin/paclitaxel may be as effec-\ntive as BEP), bleomycin should not be given to patients> 40years\nold or with pre-existing pulmonary disease [III, A].\nFor SLCTs, postoperative adjuvant ChT should be considered\nfor those patients with stage I poorly differentiated or with heter-\nologous elements [IV, B].\nSmall cell carcinomas of the ovary hypercalcaemic\ntype\nThere is no international consensus regarding the optimal treat-\nment of SCCOHT; a multimodal approach including ChT [III, B],\nradical surgery [IV, A] and possibly RT [IV, C] is often proposed", "section": "Yolk sac tumour", "page_from": 8, "page_to": 8, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "a642261a6869dd0223ad1a30236067a025ca81ecd58263e79875e2401e3da114"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000028", "text": "type\nThere is no international consensus regarding the optimal treat-\nment of SCCOHT; a multimodal approach including ChT [III, B],\nradical surgery [IV, A] and possibly RT [IV, C] is often proposed\n(Figure 6). However, no randomised studies have been conducted\nto date, and the available published data are composed of case\nreports or small retrospective series with very heterogeneous man-\nagement strategies [35].\nSCCOHTs are particularly chemosensitive at the outset but\nthere is a risk for a rapid relapse. The choice of regimen is gener-\nally extrapolated from data in small cell lung carcinoma. A com-\nbination of a cisplatin and etoposide-based therapy is generally\nconsidered most appropriate [III, B] [23, 36]. More recently,\nHDCT for patients who achieved a complete response (CR; after\nsurgery and/or ChT) with autologous stem cell transplantation\n(ASCT) rescue has been proposed and is associated with better\nsurvival [II, C] [24, 36, 37].\nManagement of advanced disease\nGerm cell tumours\nFertility-sparing surgery should also be considered in advanced\nstages disease as cure rates remain high [IV, B]. The aim of surgery is", "section": "Yolk sac tumour", "page_from": 8, "page_to": 8, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "70f351c6c51281211feff2990caeb9883bdb7750835bdad21a7b24793467ccb2"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000029", "text": "Management of advanced disease\nGerm cell tumours\nFertility-sparing surgery should also be considered in advanced\nstages disease as cure rates remain high [IV, B]. The aim of surgery is\nto remove as much gross tumour as possible; however, the proce-\ndure should be moderated to avoid delays in postoperative ChT and\nTable 5. Active surveillance programme in the management of ovarian GCTs\nTime period\nExamination\nPelvic US\nTumour markers\nChest X-ray\nCT chest\nabdomen pelvis\n1st year\nmonthly\n2 monthly\nevery 2 weeks\n(ﬁrst 6 months)\nand then monthly\n2 monthly\n1 montha\n3 monthsb\n12 months\n2nd year\n2 monthly\n4 monthly\n2 monthly\n4 monthly\n3rd year\n3 monthly\n6 monthly\n3 monthly\n6 monthly\n4th year\n4 monthly\n4 monthly\n8 monthly\n5th to 10th year\n6 monthly\n6 monthly\nannually\naIf not carried out preoperatively.\nbIf clear—second look laparoscopy if inadequate staging/immature teratoma.\nCT, computed tomography; GCT, germ cell tumour; US, ultrasound.\nSuggested surveillance programme based on Mount Vernon proposal. Modiﬁed from [32] with permission.\nTable 6. Toxicity of BEP and long-term complications\nPulmonary toxicity, decreased DLCO\nAML\nNeuropathy\nRaynaud’s disease\nTinnitus\nHigh tone hearing loss", "section": "Yolk sac tumour", "page_from": 8, "page_to": 8, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "0f8714fe6fe32169be2e8827b9fa3c2ef195b3a325d5e62d8607cbbf49dc2173"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000030", "text": "Table 6. Toxicity of BEP and long-term complications\nPulmonary toxicity, decreased DLCO\nAML\nNeuropathy\nRaynaud’s disease\nTinnitus\nHigh tone hearing loss\nGonadal dysfunction\nCardiovascular disease/Hypertension\nNephrotoxicity\nOsteoporosis after radical surgery for young patients\nAML, acute myeloid leukaemia; BEP, bleomycin/etoposide/cisplatin;\nDLCO, diffusing capacity of the lungs for carbon monoxide.\nClinical Practice Guidelines\nAnnals of Oncology\niv8 | Ray-Coquard et al.\nVolume 29 | Supplement 4 | October 2018", "section": "Yolk sac tumour", "page_from": 8, "page_to": 8, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "18a59eb92370cf16e3117a6b7bf4d53f5331af93808bcba146f860fe272c3207"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000031", "text": "Granulosa cell tumour\nStage IA\nStage IC1\nStage IC2-3\nStage IIA-IV\nFertility-sparing surgery\nStaging\n[III, A]\nStandard follow-up\nAdjuvant ChT [III, A]\nBEP x 3 cycles\nEP if > 40 years\nor\nCarboplatin/paclitaxel\nx 6 cycles\nAdjuvant ChT [IV, C]\nBEP x 3 cycles\nEP if > 40 years\n[III, A]\nor\nCarboplatin/paclitaxel\nx 6 cycles\n[III, B]\nor\nPlatinum agent alone\n[III, A]\nTAH/BSO\nStaging\nDebulking\nor\nFertility-sparing surgery\nin selected cases\n[III, A]\nTAH/BSO\nStaging\nDebulking\nor\nFertility-sparing surgery\nin selected cases\n[III, A]\nTAH/BSO\nStaging\nDebulking\n[III, A]\nActive\nsurveillance*\nFigure 4. Management of SCSTs of the ovary—granulosa cell tumour.\n*See Table 5.\nOptional\nBEP, bleomycin/etoposide/cisplatin; BSO, bilateral salpingo-oophorectomy; ChT, chemotherapy; EP, etoposide/cisplatin; SCST, sex cord-stromal\ntumour; TAH, total abdominal hysterectomy.\nAnnals of Oncology\nClinical Practice Guidelines\nVolume 29 | Supplement 4 | October 2018\ndoi:10.1093/annonc/mdy001 | iv9", "section": "Granulosa cell tumour", "page_from": 9, "page_to": 9, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "937b904b2c99c7947826aec8b19bf18d3d20c47edda8fcc5751919b9e576ed30"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000032", "text": "Sertoli-Leydig cell tumour\nStage IA\n> Stage IA\nYoung patients\nNo\nYes\nSelected cases\nWith poorly differentiated or\nheterologous elements\nNo\nYes\nAdjuvant ChT [IV, B]\nBEP\nEP if > 40 years\n[III, A]\nor\nCarboplatin/paclitaxel\nx 6 cycles\n[III, B]\nStandard follow-up\nAdjuvant ChT [III, B]\nBEP x 3–4 cycles\nEP if > 40 years\nor\nCarboplatin/paclitaxel x 6 cycles\nTAH/BSO\nStaging\n[III, A]\nFertility-sparing surgery\nStaging\n[III, A]\nFertility-sparing surgery\n[III, A]\nTAH/BSO\nStaging\nDebulking\n[III, A]\nFigure 5. Management of SCSTs of the ovary—Sertoli–Leydig cell tumour.\nBEP, bleomycin/etoposide/cisplatin; BSO, bilateral salpingo-oophorectomy; ChT, chemotherapy; EP, etoposide/cisplatin; SCST, sex cord-stromal\ntumour; TAH, total abdominal hysterectomy.\nClinical Practice Guidelines\nAnnals of Oncology\niv10 | Ray-Coquard et al.\nVolume 29 | Supplement 4 | October 2018", "section": "Sertoli-Leydig cell tumour", "page_from": 10, "page_to": 10, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "8576ab8c28fd3112ef30f1b827fe0faf9d84242622fb1f600c51490bbc813aa6"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000033", "text": "SCCOHT\nStage I-II\nStage III-IV\nTAH/BSO/Staging\n[IV, A]\nAdjuvant ChT [III, B]\nCisplatin-etoposide-based\nRELAPSE:\nCyclophosphamide/doxorubicin/vincristine [V, B]\nTopotecan [V, C]\nPhase I trial\nTAH/BSO/Staging\n[IV, A]\nDebulking feasible\nNo\nYes\nDebulking  [IV, A]\nNeoadjuvant ChT [IV, C]\nCisplatin-etoposide-based\nAdjuvant ChT [III, B]\nCisplatin-etoposide-based\nDebulking  [IV, A]\nComplete response/resection\nHDCT + ASCT\nin selected cases\n[II, C]\nYes\nNo\nTo be discussed\nPelvic RT [IV, C]\nHDCT + ASCT\nin selected cases\n[II, C]\nPelvic RT [IV, C]\nFigure 6. Management of SCCOHT.\nOptional\nASCT, autologous stem cell transplantation; BSO, bilateral salpingo-oophorectomy; ChT, chemotherapy; HDCT, high-dose chemotherapy;\nRT, radiotherapy; SCCOHT, small cell carcinomas of the ovary hypercalcaemic type; TAH, total abdominal hysterectomy.\nAnnals of Oncology\nClinical Practice Guidelines\nVolume 29 | Supplement 4 | October 2018\ndoi:10.1093/annonc/mdy001 | iv11", "section": "SCCOHT", "page_from": 11, "page_to": 11, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "3b9d699568ee857f0120e9cffcc030b021573faf66b9efa276c7bbc1d11e3a21"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000034", "text": "Table 7. Summary of recommendations\nDiagnosis and pathology/molecular biology\n• Diagnostic work-up should include pelvic ultrasound, abdomino-pelvic CT scan and chest X-ray and PET scan in selected cases (GCTs) [III, B]\n• In young adult patients, hCG, a-FP, LDH and inhibin B levels, full blood count and liver and renal function tests should be carried out\n• In case of suspected gonadoblastomas, a preoperative karyotype should be obtained on all premenarche girls\n• Histological second opinion by an expert pathologist should always be considered. Diagnosis can be made on conventional histological material [V, B]\n• Neoplasms of pure ovarian stroma: in morphologically ambiguous cases, an immunopanel of inhibin alpha, calretinin and FOXL2, plus mutational analysis\nfor FOXL2 (402C-G), is useful to conﬁrm AGCTs [V, B]\nStaging and risk assessment\n• A surgical approach can be carried out through open route or, in selected cases, by laparoscopy and robotics approaches, thereby avoiding tumour rup-\nture during surgery\n• A careful examination of the abdominal cavity is required", "section": "SCCOHT", "page_from": 12, "page_to": 12, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "2686de38f82a1c606c536d0b2d946bca63801de466b12d1e2d154ef4577599d5"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000035", "text": "ture during surgery\n• A careful examination of the abdominal cavity is required\n• The staging procedure includes infracolic omentectomy, biopsy of the diaphragmatic peritoneum, paracolic gutters, pelvic peritoneum and peritoneal\nwashings (macroscopic stage I disease)\n• Unilateral salpingo-oophorectomy with preservation of the contralateral ovary and the uterus is considered an adequate surgical treatment for patients\nwith GCTs. This should be considered even in advanced disease because of the sensitivity of the tumour to ChT [IV, B]. No systematic ovarian biopsy is\nnecessary when the contralateral ovary is macroscopically normal [III, A]\n• Given the very high chemosensitivity of GCTs, potential nodal metastasis should be cured by adjuvant ChT in these patients [III, A]\n• Nodal dissection should be carried out only if evidence of nodal abnormality [III, A]\n• For SCSTs, retroperitoneal evaluation is not mandatory [III, A]\n• An endometrial curettage must be carried out to rule out concomitant uterine cancers in patients with granulosa cell tumours [IV, B]\n• Conservative surgery is also an acceptable approach in young patients with stage I SCSTs [IV, B]", "section": "SCCOHT", "page_from": 12, "page_to": 12, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "896a555fdac214db2a3f6b40c210a8460de8e49dcc3dc03b916b320236a647c1"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000036", "text": "• Conservative surgery is also an acceptable approach in young patients with stage I SCSTs [IV, B]\n• In postmenopausal women and in patients with advanced-stage disease or with bilateral ovarian involvement, abdominal hysterectomy and bilateral\nsalpingo-oophorectomy should be carried out with careful surgical staging for SCST [III, A]\nEarly-stage GCTs: management\n• Stage IA pure dysgerminoma should be treated with surgery only [III, A]\n• Patients with stage IA grade 1 immature teratoma do not require further adjuvant ChT after adequate surgical staging [III, A]\n• Adjuvant ChT in stage IA-IC G2-G3 immature teratoma, stage IA-IB YST with negative postoperative tumour markers and IB-IC dysgerminomas is recom-\nmended but active surveillance is an option [III, B]\n• 5-day BEP is the most used regimen [III, A]\n• The close surveillance schedule involves regular clinical review with clinical examination, radiological imaging including abdomen-pelvic intravaginal\nsonography at regular intervals and the monitoring of tumour markers to detect relapse over a period of 10 years, with a gradual increase of the interval\nbetween clinical appointments [III, C]", "section": "SCCOHT", "page_from": 12, "page_to": 12, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "2c83e8ccde7e27e4ff4651bff97ca0b6c657b0df01bcbf51c1e1c0ec5fa43942"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000037", "text": "sonography at regular intervals and the monitoring of tumour markers to detect relapse over a period of 10 years, with a gradual increase of the interval\nbetween clinical appointments [III, C]\nAdvanced-stage and recurrent GCTs: management\n• Fertility-sparing surgery should be considered also in advanced stages [IV, B]. The aim of surgery is to remove as much gross tumour as possible; however,\nthe procedure should be moderated to avoid delays in postoperative ChT and long-term morbidity\n• In postmenopausal women with advanced-stage disease or with bilateral ovarian involvement, abdominal hysterectomy and bilateral salpingo-oophorec-\ntomy could be carried out with careful surgical staging [III, A]\n• Platinum-based regimens are the treatment of choice with the BEP regimen being the most widely used, generally, three cycles of 5-day BEP regimen in\ncompletely resected disease and four cycles (bleomycin should be omitted to reduce the risk of lung toxicity after the third cycle) for patients with macro-\nscopic residual disease [III, A]\n• In patients previously treated with platinum, with platinum-sensitive relapse (progression > 4–6 weeks after completion of ChT), combinations with", "section": "SCCOHT", "page_from": 12, "page_to": 12, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "1ed272d534323f81a93788abd6ce2af515ca35c10099864c7a2427c3f32bb818"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000038", "text": "scopic residual disease [III, A]\n• In patients previously treated with platinum, with platinum-sensitive relapse (progression > 4–6 weeks after completion of ChT), combinations with\nplatinum should be considered [IV, C]\n• Patients resistant to a cisplatin-based combination may receive VAC or paclitaxel/gemcitabine or gemcitabine/oxaliplatin as salvage therapy [IV, C]\n• HDCT for recurrent ovarian GCTs may result in durable and prolonged remissions [IV, C]\n• Any resectable residual disease should be removed, particularly for patients with normal serum marker and for patients with immature teratoma in order\nto avoid the growing teratoma syndrome [III, A]\nEarly-stage SCSTs: management\n• Stage IA granulosa cell tumour disease has an excellent prognosis after surgery alone and does not require adjuvant therapy [III, A]\n• Adjuvant therapy should be considered for juvenile granulosa tumour stage IC patients [IV, B] or for AGCT stage IC2-IC3 patients [IV, C]. In these cases,\nplatinum-based ChT is the treatment of choice [III, A]\n• For SLCTs, postoperative adjuvant ChT should be considered for patients with stage I poorly differentiated or heterologous elements (mesenchymal type)\n[IV, B]", "section": "SCCOHT", "page_from": 12, "page_to": 12, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "2e24cbd9d89607e508fcf8a6e245b09dbe9492594c6345b9991616e02c394843"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000039", "text": "• For SLCTs, postoperative adjuvant ChT should be considered for patients with stage I poorly differentiated or heterologous elements (mesenchymal type)\n[IV, B]\n• BEP is the most commonly used regimen [III, A]. Alternative ChT options include paclitaxel and carboplatin [III, B], EP, CAP or platinum agent alone [III, A]\nAdvanced-stage and recurrent SCSTs: management\n• Debulking surgery remains the most effective treatment of advanced or recurrent granulosa cell tumour [III, A]\n• Platinum-based ChT is currently used for patients with advanced-stage SCSTs or recurrent disease [III, A]\n• BEP regimen for three cycles or six cycles of carboplatin/paclitaxel is recommended for postoperative ChT and patients with recurrent SCSTs [III, A]\nContinued\nClinical Practice Guidelines\nAnnals of Oncology\niv12 | Ray-Coquard et al.\nVolume 29 | Supplement 4 | October 2018", "section": "SCCOHT", "page_from": 12, "page_to": 12, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "3846f9cc184c64acea4d441bcf5930c10be8b2cfc7de757409ec50dabbd05e1f"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000040", "text": "long-term morbidity. These tumours are highly chemosensitive but\ngrow rapidly and may grow back if there is a delay in starting ChT.\nPlatinum-based regimens have been the treatment of choice\nand the 5-day-BEP regimen is the most widely used regimen [38].\nWhile the optimal number of cycles of BEP has not been fully\nestablished in randomised trials, three cycles of BEP for com-\npletely resected stage I disease and four cycles for those with more\nadvanced disease are recommended [III, A] [2, 39]. Bleomycin\nshould not be given to those > 40 years of age or with pre-existing\npulmonary disease, given the risk of drug-related lung injury with\nan approximate mortality rate of 3% [III, A].\nAlternative ChT regimens [POMB/ACE (cisplatin/vincristine/\nmethotrexate/bleomycin/actinomycin D/cyclophosphamide/eto-\nposide) and CBOP/BEP (carboplatin/bleomycin/vincristine/cis-\nplatin/BEP)] have been evaluated, particularly in high-risk\npatients, reporting high activity and impacting toxicity: unfortu-\nnately, none of them has been compared with BEP in randomised\ntrials. A phase II Gynecologic Oncology Group (GOG) trial\nreported high activity with an acceptable toxicity proﬁle for a", "section": "Platinum-based regimens have been the treatment of choice", "page_from": 13, "page_to": 13, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "3e7b4ba1de3caf370abd8b222eafb3f2109c99ada920a0297827a943f1891b1e"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000041", "text": "nately, none of them has been compared with BEP in randomised\ntrials. A phase II Gynecologic Oncology Group (GOG) trial\nreported high activity with an acceptable toxicity proﬁle for a\ncarboplatin–etoposide combination in the adjuvant setting\nof completely resected stages I–III dysgerminomas [40].\nDysgerminomas are very sensitive to RT; however, its use is lim-\nited to selected cases because of the negative impact on fertility.\nIn patients with platinum-sensitive relapse (progression\n> 4–6 weeks after completion of ChT), ifosfamide/platinum (IP)\nwith or without paclitaxel (P) should be considered as second-\nline treatment [IV, C] [41]. Further active ChT regimens include:\nvinblastine/ifosfamide/cisplatin (VeIP) and cisplatin/vinblastine/\nbleomycin (PVB) [IV, C] [42]. Patients resistant to a cisplatin-\nbased combination may receive vincristine/actinomycin D/cyclo-\nphosphamide (VAC) or paclitaxel/gemcitabine or gemcitabine/\noxaliplatin as salvage therapy [IV, C].\nAlthough there is a role for ASCT in relapsed testicular cancer, it\nis not the standard of care for women with relapsed or recurrent\nmalignant ovarian GCTs and its role remains undeﬁned because of", "section": "Platinum-based regimens have been the treatment of choice", "page_from": 13, "page_to": 13, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "c840a8b2db49465bf3d0e959c97d1a4d691cd2d875a6905484133f0fb5e35345"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000042", "text": "Although there is a role for ASCT in relapsed testicular cancer, it\nis not the standard of care for women with relapsed or recurrent\nmalignant ovarian GCTs and its role remains undeﬁned because of\nthe paucity of prospective data. A recent report suggests that\nHDCT for recurrent ovarian GCTs may result in durable and pro-\nlonged remissions [IV, C]. In a retrospective series, Reddy\nAmmakkanavar et al. [43] treated 13 patients with recurrent\nmalignant ovarian GCTs from 1990 to 2013. All patients had expe-\nrienced disease progression after standard cisplatin combination\ntreatment. HDCT consisted of tandem courses of carboplatin\nTable 7. Continued\n• Patients with steroid cell tumours that are pleomorphic, large, at an advanced stage or with an increased mitotic count should be treated with additional\npostoperative platinum-based ChT, either BEP (if not previously used) or a taxane–platinum combination [IV, C]\n• Response to GnRH agonists, tamoxifen, progestin and AIs has been reported and could be an interesting option speciﬁcally for adult GCT [IV, B]\n• For patients with persistent SLCTs, adjuvant ChT should be considered [III, B]\nEarly and advanced SCCOHT: management", "section": "Platinum-based regimens have been the treatment of choice", "page_from": 13, "page_to": 13, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "338edebc2a2edea3f4f929b2cd3427a49c3619858772c0e22d34bbf3ccb9dbe2"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000043", "text": "• For patients with persistent SLCTs, adjuvant ChT should be considered [III, B]\nEarly and advanced SCCOHT: management\n• All suspected cases should beneﬁt from a review by an expert pathologist and be discussed in a specialised tumour board [V, A]\n• Optimal treatment: a multimodal approach including ChT [III, B], radical surgery [IV, A], HDCT [II, C] and RT [IV, C]\n• Debulking surgery (initial or interval) remains the most effective treatment [IV, A]\n• Combination of a cisplatin- and etoposide-based therapy is the most appropriate for all stages [III, B]\n• The use of pelvic RT, either concurrently or sequentially to HDCT and ASCT, may be considered for patients after surgery [IV, C]\n• Efforts should be made to treat patients in a more homogeneous way through national and international networks [V, A]\nResponse evaluation and follow-up after initial treatment\n• Serum tumour markers (hCG, a-FP, LDH, CA 125 and inhibin B) can correlate with tumour response during ChT [V, A]\n• A CT scan of the abdomen, pelvis and chest (in case of suspected lung metastases) and pelvic ultrasound are the most common and useful imaging\ntechniques to evaluate the response to ChT [V, A]", "section": "Platinum-based regimens have been the treatment of choice", "page_from": 13, "page_to": 13, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "b5ddb0e493ae68501f06ab65f5958558b0cfd0dfdb70c71e2be81ef9c9ffe38e"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000044", "text": "• A CT scan of the abdomen, pelvis and chest (in case of suspected lung metastases) and pelvic ultrasound are the most common and useful imaging\ntechniques to evaluate the response to ChT [V, A]\n• For GCT, follow-up visits must include history, physical examination with pelvic examination and tumour markers every 3 months for the ﬁrst 2 years,\nthen every 6 months during the third year and then yearly until progression [V, A]\n• For SCSTs, follow-up visits including physical exam and tumour markers must be carried out every 6 months starting from the third year and this frequency\nshould be maintained indeﬁnitely [V, B]\n• A pelvic ultrasound should be carried out every 6 months in those patients who have undergone fertility-sparing surgery, whereas a CT scan of the\nabdomen and pelvis is carried out according to clinical indication\n• PET scan for tumour response evaluation or follow-up is not yet recommended [V, D]\nFertility and hormone replacement\n• Oocyte cryopreservation is an option for patients scheduled to receive ChT [V, C]\n• Hyperstimulation followed by oocyte cryopreservation 12 months after the end of ChT is another option [V, C]", "section": "Platinum-based regimens have been the treatment of choice", "page_from": 13, "page_to": 13, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "a88e12cde9a69a55ca178a516f62ecffb246257ccec652b326b12ee088c5f4e5"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000045", "text": "• Oocyte cryopreservation is an option for patients scheduled to receive ChT [V, C]\n• Hyperstimulation followed by oocyte cryopreservation 12 months after the end of ChT is another option [V, C]\n• Fertility preservation should not jeopardise the oncological management\n• HRT may be used safely for many GCTs [V, A]\n• An HRT approach should be avoided for SCST [V, D]\na-FP, alpha foetoprotein; AGCT, adult granulosa cell tumour; AI, aromatase inhibitor; ASCT, autologous stem cell transplantation; BEP, bleomycin/etoposide/\ncisplatin; CA 125, cancer antigen 125; CAP, cyclophosphamide/doxorubicin/cisplatin; ChT, chemotherapy; CT, computed tomography; EP, etoposide/cisplatin;\nGCT, germ cell tumour; GnRH, gonadotropin-releasing hormone; hCG, human chorionic gonadotropin; HDCT, high-dose chemotherapy; HRT, hormone\nreplacement therapy; LDH, lactate dehydrogenase; PET, positron emission tomography; RT, radiotherapy; SCCOHT, small cell carcinoma of the ovary hypercal-\ncaemic type; SCST, sex cord-stromal tumour; SLCT, Sertoli-Leydig cell tumour; VAC, vincristine/actinomycin D/cyclophosphamide; YST, yolk sac tumour.\nAnnals of Oncology\nClinical Practice Guidelines", "section": "Platinum-based regimens have been the treatment of choice", "page_from": 13, "page_to": 13, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "b6fac84226d91e6b298849d2cd9755b3a9f03bda0da44b48d447983f76efa3fb"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000046", "text": "caemic type; SCST, sex cord-stromal tumour; SLCT, Sertoli-Leydig cell tumour; VAC, vincristine/actinomycin D/cyclophosphamide; YST, yolk sac tumour.\nAnnals of Oncology\nClinical Practice Guidelines\nVolume 29 | Supplement 4 | October 2018\ndoi:10.1093/annonc/mdy001 | iv13", "section": "Platinum-based regimens have been the treatment of choice", "page_from": 13, "page_to": 13, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "2eed06489f21138187637d73e584cee573a2827c7ad280f924a28c43bbc583d6"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000047", "text": "700 mg/m2 and etoposide 750 mg/m2 intravenously (i.v.) daily for\nthree consecutive days followed by stem cell infusion. Seven\npatients achieved CR with four of these seven patients remaining\ndisease free at 12, 22, 120 and 270 months from treatment.\nAny resectable residual disease should be removed, particularly\nfor patients with normal serum marker in which residual disease is\npresent on imaging after adjuvant therapy and for patients with\nimmature teratoma, to avoid growing teratoma syndrome [III, A].\nThe role of secondary cytoreductive surgery for patients with\nrecurrent or progressive ovarian GCT remains controversial.\nUnlike males, females who have a relapse with malignant disease\nafter primary ChT for GCTs have a poor prognosis.\nThe role of the new targeted agents in GCTs is yet to be dem-\nonstrated. Targeted agents already investigated in testicular\ntumours and of potential interest include tyrosine kinase inhibi-\ntors (imatinib and sunitinib) and anti-angiogenic agents (beva-\ncizumab) [44]. These recent studies involving targeted therapies\nhave been inconclusive. Nevertheless, studies of the manage-\nment of refractory GCTs are ongoing, with a focus on optimal", "section": "Platinum-based regimens have been the treatment of choice", "page_from": 14, "page_to": 14, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "aecd736995c1e8933c5501feb180d318b738eeb4796075505a41aacabcc64967"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000048", "text": "cizumab) [44]. These recent studies involving targeted therapies\nhave been inconclusive. Nevertheless, studies of the manage-\nment of refractory GCTs are ongoing, with a focus on optimal\nutilisation of HDCT and ASCT, as well as the role of immune\ncheckpoint inhibitors in refractory GCTs [45]. Studies aiming\nto identify the patients who may beneﬁt from more intensive\ntreatment up front to prevent the development of refractory dis-\nease are also in progress for testicular GCTs, and the results may\nbe useful for ovarian GCT patients [46].\nSex cord-stromal tumours\nDebulking surgery, whenever feasible, remains the most effective\ntreatment for metastatic or recurrent granulosa cell tumours [III,\nA]. Platinum-based ChT is currently used for patients with\nadvanced-stage SCSTs or recurrent disease, with an overall response\nrate of 63%–80% [47]. Unfortunately, most patients with advanced\ndisease do not have durable remissions. Patients with advanced dis-\nease have poor prognosis and they are, therefore, treated with adju-\nvant therapy, although the data are very limited [IV, C]. The BEP\nregimen for three cycles or carboplatin/paclitaxel for six cycles is cur-", "section": "Platinum-based regimens have been the treatment of choice", "page_from": 14, "page_to": 14, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "58d71a7a5f24672faf5cd23386ecd61450ed1d4cf0b4315228a00fbc15e4f54b"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000049", "text": "vant therapy, although the data are very limited [IV, C]. The BEP\nregimen for three cycles or carboplatin/paclitaxel for six cycles is cur-\nrently recommended for adjuvant postoperative ChT and for\npatients with recurrent SCSTs [III, A].\nPatients with steroid cell tumours that are pleomorphic, large,\nat an advanced stage or with non-operable residual disease or\nwith an increased mitotic count should be treated with addi-\ntional postoperative platinum-based ChT, either with BEP (if\nnot previously used), or with a taxane-platinum combination\n[IV, C].\nThe GOG is currently conducting a randomised phase II trial\nof BEP versus the combination of paclitaxel and carboplatin for\npatients with newly diagnosed and ChT-naı¨ve recurrent meta-\nstatic SCSTs of the ovary [48].\nAlternative ChT options include: PVB, EP, CAP, VAC and\nweekly paclitaxel for relapsed patients after platins. There are lim-\nited data regarding the utility of ChT in patients with persistent\nSLCTs, but responses in patients with measurable disease have\nbeen reported [III, B].\nGiven the functional hormonal nature of granulosa cell\ntumours that express steroid hormone receptors, there is some\nrational\nfor\na\nhormone-based", "section": "Platinum-based regimens have been the treatment of choice", "page_from": 14, "page_to": 14, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "dc8e1ba877a4400f84116eb6c4e45983624db3f60234fc6a896899e311e0be89"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000050", "text": "been reported [III, B].\nGiven the functional hormonal nature of granulosa cell\ntumours that express steroid hormone receptors, there is some\nrational\nfor\na\nhormone-based\napproach.\nResponse\nto\ngonadotropin-releasing hormone (GnRH) agonists, tamoxifen,\nprogestin and aromatase inhibitors (AIs) has been reported. In a\nrecent review, Van Meurs et al. reported the results of 31 patients\ntreated with hormone therapy; a CR was described in 25.8% of\npatients and a partial response in 45.2% [49]. Despite limited\navailable data, hormone therapy appears to be a useful alternative\ntreatment for patients with advanced-stage or recurrent AGCTs\n[IV, B]. The role of AIs for relapsed granulosa cell tumours is\nbeing assessed in the multicentre phase II PARAGON trial\n(ANZGOG-0903).\nAnti-angiogenic agents have also been investigated in patients\nwith recurrent AGCT, due to the overexpression of vascular\nendothelial growth factor and vascularity of these tumours. A\nrecent study at the MD Anderson Cancer Center seems to con-\nﬁrm the potential activity of bevacizumab [response rate 17%,\nstable disease (SD) 77%] [50], although the study was conducted\nin only 36 patients [III, C]. The GINECO group (Groupe", "section": "Platinum-based regimens have been the treatment of choice", "page_from": 14, "page_to": 14, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "090e983842255d67eb1cf3a862302b045c4502f67ab2da7cbfa1012e5ee5b9c0"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000051", "text": "ﬁrm the potential activity of bevacizumab [response rate 17%,\nstable disease (SD) 77%] [50], although the study was conducted\nin only 36 patients [III, C]. The GINECO group (Groupe\nd’Investigateurs Nationaux pour les Etudes des Cancers de\nl’Ovaire) is currently conducting a phase II trial (ALIENOR-\nENGOT-ov7/GINECO), to explore the clinical beneﬁt of adding\nbevacizumab to weekly paclitaxel followed by bevacizumab as\nmaintenance versus weekly paclitaxel followed by observation in\npatients with relapsed SCSTs [51].\nSmall cell carcinomas of the ovary hypercalcaemic\ntype\nFor selected patients with bulky stage III disease or stage IV disease\nwhere primary debulking surgery is not considered to be achievable,\nthe use of neoadjuvant ChT may be considered on an individual\nbasis after discussion with the tumour board [IV, C].\nTable 8. Table of levels of evidence and grades of recommendation\n(adapted from the Infectious Diseases Society of America-United States\nPublic Health Service Grading Systema)\nLevels of evidence\nI\nEvidence from at least one large randomised, controlled trial of good\nmethodological quality (low potential for bias) or meta-analyses of", "section": "Platinum-based regimens have been the treatment of choice", "page_from": 14, "page_to": 14, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "11ba2ba11c0b497be621c75ae09f972736a3db1f97818ca24d5504bc1b3b3aa2"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000052", "text": "Public Health Service Grading Systema)\nLevels of evidence\nI\nEvidence from at least one large randomised, controlled trial of good\nmethodological quality (low potential for bias) or meta-analyses of\nwell-conducted randomised trials without heterogeneity\nII\nSmall randomised trials or large randomised trials with a suspicion of\nbias (lower methodological quality) or meta-analyses of such trials\nor of trials demonstrated heterogeneity\nIII Prospective cohort studies\nIV Retrospective cohort studies or case–control studies\nV\nStudies without control group, case reports, expert opinions\nGrades of recommendation\nA\nStrong evidence for efﬁcacy with a substantial clinical beneﬁt,\nstrongly recommended\nB\nStrong or moderate evidence for efﬁcacy but with a limited clinical\nbeneﬁt, generally recommended\nC\nInsufﬁcient evidence for efﬁcacy or beneﬁt does not outweigh the\nrisk or the disadvantages (adverse events, costs, . . .), optional\nD Moderate evidence against efﬁcacy or for adverse outcome, generally\nnot recommended\nE\nStrong evidence against efﬁcacy or for adverse outcome, never\nrecommended\naBy permission of the Infectious Diseases Society of America [58].\nClinical Practice Guidelines", "section": "Platinum-based regimens have been the treatment of choice", "page_from": 14, "page_to": 14, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "8a872a7ba6d9ce6a81fd04c6538c34aa08cb02900fc7cffaa148f336a937e7bb"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000053", "text": "not recommended\nE\nStrong evidence against efﬁcacy or for adverse outcome, never\nrecommended\naBy permission of the Infectious Diseases Society of America [58].\nClinical Practice Guidelines\nAnnals of Oncology\niv14 | Ray-Coquard et al.\nVolume 29 | Supplement 4 | October 2018", "section": "Platinum-based regimens have been the treatment of choice", "page_from": 14, "page_to": 14, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "8e5e24a7946e8b0cbab66984a821b4594d435dc5df54d153c6ecf865bbf31ddb"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000054", "text": "A combination of a cisplatin and etoposide-based therapy is\ngenerally considered most appropriate [III, B] [22, 36]. As\nreported in early stage, HDCT for patients who underwent a CR\n(after surgery and/or ChT) with ASCT rescue has been proposed\nand is associated with better prognosis [II, C] [23, 34, 37]. Even\nwith intensive regimens, prognosis remains dismal, and despite\nfrequent initial responses to ChT, relapses are frequent and tend\nto be refractory to second-line ChT.\nThe management of relapsed disease is often very challenging,\nand prolonged remissions are never achieved with second-line\nChT regimens usually used in small cell lung carcinomas. Several\nschedules have been reported including the combination of\ncyclophosphamide, doxorubicin and vincristine [V, B]. There are\nanecdotal reports on carboplatin and paclitaxel including\ndose-dense regimes, and topotecan has also shown some modest\nactivity as in small cell lung cancers [V, C]. To date, no targeted\ntherapies have been tested in SCCOHT. Second-line treatment is\nlikely to achieve short remission rates, and beyond that, patients\nshould be considered for phase I trials if they remain of good\nperformance status.", "section": "A combination of a cisplatin and etoposide-based therapy is", "page_from": 15, "page_to": 15, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "28b7e76552b0bc12a87a5fe199caa409520f17358e93d6665645cdff0304bdea"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000055", "text": "likely to achieve short remission rates, and beyond that, patients\nshould be considered for phase I trials if they remain of good\nperformance status.\nFollow-up, long-term implications and\nsurvivorship\nResponse evaluation and follow-up programme for\npost-ChT\nGerm cell tumours. The surveillance follow-up programme for\npatients not undergoing postoperative ChT has been detailed\npreviously. For patients undergoing ChT, serum tumour markers\n(hCG, a-FP, LDH, CA 125 and inhibin B) can accurately correlate\nwith tumour response during ChT [V, A]. A CT scan of the abdo-\nmen, pelvis and chest (in case of suspected lung metastases) and\npelvic ultrasound are the most common and useful imaging tech-\nniques to evaluate the response to ChT in patients with measura-\nble disease [V, A]. Approximately 75% of GCT recurrences occur\nwithin the ﬁrst year after initial management; the peritoneal cav-\nity is the most common site of recurrence, while retroperitoneal\nlymph node involvement is very uncommon. Given that the\nmajority of women with GCTs have an excellent survival\noutcome, persistence of long-term effects of treatment is highly\nsigniﬁcant. The most frequent side effects of BEP included pul-", "section": "A combination of a cisplatin and etoposide-based therapy is", "page_from": 15, "page_to": 15, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "fbd89806378ab9be7ca8cf61c8c4f90a25bb6f3cf619a9c269a1907f752b4181"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000056", "text": "majority of women with GCTs have an excellent survival\noutcome, persistence of long-term effects of treatment is highly\nsigniﬁcant. The most frequent side effects of BEP included pul-\nmonary toxicity, decreased diffusing capacity of the lungs for car-\nbon monoxide (DLCO), acute myeloblastic leukaemia (AML),\nneuropathy, Raynaud’s disease, tinnitus, high tone hearing loss,\ngonadal dysfunction, cardiovascular disease/hypertension and\nnephrotoxicity (Table 6). One of the most ominous late effects of\nChT, particularly for young survivors, is the risk of secondary\nmalignancies. Contrary to what is known for testicular cancer\nsurvivors, no study so far has analysed the risk of a solid second\ncancer in GCTs. Recently, the Cancer Registry of Norway has\nreported the cumulative incidence of a second cancer in 10-year\nGCT survivors [19]. A second cancer was diagnosed in 23 of 139\nsurvivors who underwent cytotoxic treatment. Interestingly,\namong these 23 cases, 18 had received abdominal RT and 16 of\nthem had their second malignancy occur below the diaphragm.\nThree uterine tumours and two malignant melanomas occurred\namong 41 patients treated only with ChT. Due to the low number", "section": "A combination of a cisplatin and etoposide-based therapy is", "page_from": 15, "page_to": 15, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "f3c48bdeacd75838b6e9d938cb22fd3e5525dff5509e06943662d46304e20898"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000057", "text": "them had their second malignancy occur below the diaphragm.\nThree uterine tumours and two malignant melanomas occurred\namong 41 patients treated only with ChT. Due to the low number\nof cases, the role of ChT in the development of second malignan-\ncies cannot be assessed.\nFollow-up visits for GCT patients must include history, physi-\ncal and pelvic examinations and exploration of tumour markers\nevery 3 months for the ﬁrst 2 years, every 6 months during the\nthird year and then yearly until progression [V, A]. Tumour\nmarker exploration can be avoided from the third year.\nSex cord-stromal tumours. Conversely, SCSTs have an indolent\ncourse with tendency for late recurrence (the median time to\nrelapse is approximately 4–6 years), therefore patients with\nSCSTs require long-term follow-up [47]. Several reports describe\nrelapses occurring more than 20 years (up to 37 years) after diag-\nnosis. Common sites of recurrence are the upper abdomen\n(55%–70%) and the pelvis (30%–45%).\nIn the case of SCSTs, follow-up visits including physical exam\nand tumour marker exploration (e.g. inhibin B, AMH) must be\ncarried out every 6 months starting from the third year and this", "section": "A combination of a cisplatin and etoposide-based therapy is", "page_from": 15, "page_to": 15, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "6b1af368b80f78209e9896453eafc91c9075e66911d1b99ad6b572250c859553"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000058", "text": "In the case of SCSTs, follow-up visits including physical exam\nand tumour marker exploration (e.g. inhibin B, AMH) must be\ncarried out every 6 months starting from the third year and this\nfrequency should be maintained indeﬁnitely [V, B]. Pelvic ultra-\nsound should be carried out every 6 months in those patients\nwho have undergone fertility-sparing surgery. CT scan or mag-\nnetic resonance imaging (MRI) should be carried out when clini-\ncally indicated, based on symptoms or tumour marker elevation.\nThe use of PET scan for tumour response evaluation or follow-\nup is not well established yet, as this is not recommended in\nGCTs [V, D].\nFertility preservation in non-epithelial ovarian cancer. Fertility\npreservation should not jeopardise the oncological management.\nFor non-epithelial ovarian cancer, much of the literature on fer-\ntility has been focused on young women who harbour GCTs.\nGCTs account for less than 5% of all ovarian malignancies and\nare typically diagnosed in young females, at the peak of their\nreproductive age. After introduction of cisplatin-based ChT,\nmost young women with GCTs treated according to the current", "section": "A combination of a cisplatin and etoposide-based therapy is", "page_from": 15, "page_to": 15, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "8e40c9b23c34beb5e28a8d1fbe7a253eac9caad9abc1668df73d5cb39206fced"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000059", "text": "are typically diagnosed in young females, at the peak of their\nreproductive age. After introduction of cisplatin-based ChT,\nmost young women with GCTs treated according to the current\ntherapeutic approach will survive the disease. However, this suc-\ncess must be balanced against possible treatment-associated long-\nterm adverse effects, gonadal dysfunction being among the most\nfeared. The likelihood of ChT-induced amenorrhoea is based on\nthe speciﬁc administered ChT, its cumulative drug dose and\nduration of therapy. In general, cisplatin is viewed to be only\nmoderately gonadotoxic; a signiﬁcant association between\nincreased cumulative doses of cisplatin-based ChT and reduced\ngonadal function has been shown in males with germ cell cancer\n[38]. Recently, the work published by Solheim et al. has shown a\nsimilar dose-dependent risk of gonadal dysfunction in females\n[19]. This group reports that the cumulative probability of\nachieving pregnancy after treatment was signiﬁcantly higher in\nwomen who received no adjuvant treatment or no more than\nthree cycles of cisplatin-based ChT compared with those who had\n> 3 cycles of cisplatin- or non-cisplatin-based postoperative", "section": "A combination of a cisplatin and etoposide-based therapy is", "page_from": 15, "page_to": 15, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "566531184faa1dcd822c5468601e6c5d0d4dcadae46a88a597bf9ecb6b532284"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000060", "text": "women who received no adjuvant treatment or no more than\nthree cycles of cisplatin-based ChT compared with those who had\n> 3 cycles of cisplatin- or non-cisplatin-based postoperative\ntreatment. In addition, the fertility outcome, namely the return\nof menstruation and ovulation, depends on age: the younger\nthe patient, the larger the reserve of oocytes harvested after ChT\n[52]. The infertility rate reported among women attempting con-\nception after treatment for GCTs is 5%–10% [26, 53] which is\nalmost comparable to the rate among age-matched women in\nAnnals of Oncology\nClinical Practice Guidelines\nVolume 29 | Supplement 4 | October 2018\ndoi:10.1093/annonc/mdy001 | iv15", "section": "A combination of a cisplatin and etoposide-based therapy is", "page_from": 15, "page_to": 15, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "9fa492653d8106def4efcdb922325e1057a5b31ab77977645880c2017ea814ce"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000061", "text": "the general population [54]. Nevertheless, oocyte cryopreserva-\ntion is an option for patients scheduled to receive ChT [V, C].\nThe recommended approach is to postpone cancer treatment to\nenable ovulation induction and oocyte aspiration. Whenever\npossible, the retrieved oocytes should be in vitro fertilised prior\ncryopreservation, with donor sperm offered to single patients\n[55]. These frozen embryos may be used to achieve pregnancies if\nChT-related\novarian\nfailures\noccur.\nAnother\napproach\nis\ncontrolled ovarian hyperstimulation followed by oocyte cryopre-\nservation 12 months after the end of ChT, in the scenario of a\nrapid decline in ovarian reserve [V, C]. However, due to the rarity\nof GCTs, experience with this approach is limited.\nThere is an increasing evidence for efﬁcacy in reducing prema-\nture ovarian insufﬁciency with the use of GnRH agonists in\npatients with breast cancer undergoing ChT. However, there is\nno evidence in other cancers and certainly none in these rare\ndiseases [56].\nHormone replacement therapy and contraception\nChT has long-term effects on gonadal function and may lead to\novarian dysfunction and sterility. Factors such as cumulative", "section": "The recommended approach is to postpone cancer treatment to", "page_from": 16, "page_to": 16, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "51935495188857a95e4e0f46c6a7897e690139135ae7efb925957e161465285a"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000062", "text": "diseases [56].\nHormone replacement therapy and contraception\nChT has long-term effects on gonadal function and may lead to\novarian dysfunction and sterility. Factors such as cumulative\ndrug dose, duration of therapy and age at treatment inﬂuence the\nincidence of ovarian failure function. Those patients who suffer\nfrom iatrogenic menopause usually have more pronounced\nsymptoms in comparison with those following a naturally occur-\nring menopause, mainly due to the sudden cessation of ovarian\nhormone production and younger age. In this ﬁeld, the GOG car-\nried out an analysis evaluating the quality of life and the repro-\nductive and psychosocial characteristics of survivors of GCTs\ncompared with matched controls [57]. At a median follow-up of\n10.2 years, these women appeared to be free of any major physical\nillnesses compared with matched controls. The only differences\nconsisted of higher rates of reported hypertension, hypercholes-\nterolaemia and hearing loss. Among chronic functional prob-\nlems, numbness, tinnitus and Raynaud’s symptoms were\nreported more frequently by survivors. In spite of persistence of a\nfew sequelae of treatment, in general, GCT survivors enjoy a", "section": "The recommended approach is to postpone cancer treatment to", "page_from": 16, "page_to": 16, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "12946792134b3609a1fe5c89a30b70e8d87d6174ab86275d3bf83b279ef5661f"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000063", "text": "lems, numbness, tinnitus and Raynaud’s symptoms were\nreported more frequently by survivors. In spite of persistence of a\nfew sequelae of treatment, in general, GCT survivors enjoy a\nhealthy life comparable to that of controls.\nHormone replacement therapy (HRT) for germ cell and sex\ncord ovarian malignancies is important to consider; most cases\noccur in young premenopausal women who could enter the men-\nopause as a consequence of radical treatment and would be\nexposed to several decades of oestrogen deﬁciency. Symptoms of\niatrogenic menopause are usually more pronounced compared\nwith a regular menopause due to the sudden cessation of ovarian\nhormone production, younger age and additional physical and\npsychological symptoms associated with cancer therapy.\nHRT is an effective treatment mainly used for the treatment of\nvasomotor symptoms, low mood, sexual dysfunction and uro-\ngenital symptoms following the menopause. Moreover, it may\ndramatically improve physical and psychological symptoms and,\nin the end, the quality of life in cancer patients.\nAlthough, there is no trial evaluating the use of HRT in germ\ncell and sex cord ovarian cancer patients, it is generally consid-", "section": "The recommended approach is to postpone cancer treatment to", "page_from": 16, "page_to": 16, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "b77770c73b42ffcb067fa2d465130949304471da3922b97dc5284071338e54a0"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000064", "text": "in the end, the quality of life in cancer patients.\nAlthough, there is no trial evaluating the use of HRT in germ\ncell and sex cord ovarian cancer patients, it is generally consid-\nered that HRT may be used safely for GCTs [V, A]. In the case of\novarian granulosa cell tumours and other sex cord-stromal\nmalignancies, e.g. SLCTs which are thought to be hormone\ndependent, an HRT approach should be avoided following their\ndiagnosis [V, D].\nHormonal contraception is not contraindicated for women\ndiagnosed with GCTs receiving fertility-sparing treatment and\nwanting to postpone or avoid pregnancies [V, B].\nMethodology\nThese Clinical Practice Guidelines were developed in accordance\nwith the ESMO standard operating procedures for Clinical\nPractice\nGuidelines\ndevelopment\nhttp://www.esmo.org/\nGuidelines/ESMO-Guidelines-Methodology. The relevant litera-\nture has been selected by the expert authors. A summary of rec-\nommendations is presented in Table 7. Levels of evidence and\ngrades of recommendation have been applied using the system\npresented in Table 8. Statements without grading were consid-\nered justiﬁed standard clinical practice by the experts and the", "section": "The recommended approach is to postpone cancer treatment to", "page_from": 16, "page_to": 16, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "00db1d1e0b673a8b0450c7479c50433935665871b82435cb8fd117bf96bde2bd"}
{"doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000", "chunk_id": "000065", "text": "grades of recommendation have been applied using the system\npresented in Table 8. Statements without grading were consid-\nered justiﬁed standard clinical practice by the experts and the\nESMO faculty. This manuscript has been subjected to an anony-\nmous peer review process.\nDisclosure\nIRC has reported advisory board membership for Roche, Clovis,\nAstraZeneca, Tesaro, PharmaMar, Amgen, Merck Sharp &\nDohme, Vifor Pharma and has received research support from\nPharmaMar; DL has reported advisory board membership for\nRoche, Clovis, AstraZeneca and has received research support\nfrom PharmaMar; AO has reported advisory board membership\nfor Roche, Clovis, AstraZeneca and PharmaMar; NC is a member\nof the Roche speakers’ bureau; PM, JP and PP have reported no\nconﬂicts of interest.", "section": "The recommended approach is to postpone cancer treatment to", "page_from": 16, "page_to": 16, "display_name": "ESMO_CPG_NonEpithelialOvarian_2018", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "fb0e15f5c24382d34c89fd4a8bc93a6ef7fe74640dc5847e5294328e503b8efd"}
